| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S40266-015-0304-7 |
| P698 | PubMed publication ID | 26442859 |
| P50 | author | Jean-Christophe Marine | Q6169071 |
| P2093 | author name string | Joost J van den Oord | |
| Pascal Wolter | |||
| Marjan Garmyn | |||
| Hans Wildiers | |||
| Aljosja Rogiers | |||
| Cindy Kenis | |||
| Marguerite Stas | |||
| P2860 | cites work | B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion | Q22010866 |
| Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 | ||
| Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade | Q24535835 | ||
| Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib | Q24594790 | ||
| A landscape of driver mutations in melanoma | Q24603357 | ||
| Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations | Q24632064 | ||
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 | ||
| Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma | Q24679736 | ||
| RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 | ||
| Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification | Q27851656 | ||
| NRAS mutation status is an independent prognostic factor in metastatic melanoma | Q27851695 | ||
| MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study | Q27852083 | ||
| Combined vemurafenib and cobimetinib in BRAF-mutated melanoma | Q27853076 | ||
| Improved overall survival in melanoma with combined dabrafenib and trametinib | Q27853091 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Cancer statistics, 2015 | Q27860576 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion | Q28131654 | ||
| Determinants of BRAF mutations in primary melanomas | Q28191720 | ||
| Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study | Q28250432 | ||
| Hepatotoxicity with combination of vemurafenib and ipilimumab | Q28288255 | ||
| Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma | Q28378420 | ||
| Signatures of mutational processes in human cancer | Q29547191 | ||
| Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| Pembrolizumab versus Ipilimumab in Advanced Melanoma | Q29618134 | ||
| High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 | Q29619885 | ||
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Q29620033 | ||
| Genetic basis for clinical response to CTLA-4 blockade in melanoma | Q29620594 | ||
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab | Q29620596 | ||
| Nivolumab and ipilimumab versus ipilimumab in untreated melanoma | Q29620657 | ||
| Improved survival with MEK inhibition in BRAF-mutated melanoma | Q29620663 | ||
| Managing immune checkpoint-blocking antibody side effects | Q38493811 | ||
| Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials | Q38502534 | ||
| Age as a prognostic factor in the malignant melanoma population | Q38572034 | ||
| End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article | Q39353094 | ||
| Older Age is Associated with a Higher Incidence of Melanoma Death but a Lower Incidence of Sentinel Lymph Node Metastasis in the SEER Databases (2003-2011). | Q40977287 | ||
| Complete regression of primary cutaneous malignant melanoma | Q41479485 | ||
| Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. | Q41752617 | ||
| Histological regression in primary cutaneous melanoma: recognition, prevalence and significance | Q42019293 | ||
| Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. | Q42645881 | ||
| A novel transforming gene in a human malignant melanoma cell line | Q42817664 | ||
| Melanoma incidence and mortality among US whites, 1969-1999. | Q43469137 | ||
| Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma | Q43977818 | ||
| Experience with 998 cutaneous melanomas of the head and neck over 30 years | Q44773879 | ||
| Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results. | Q45904315 | ||
| KIT gene mutations and copy number in melanoma subtypes | Q46267082 | ||
| Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990-2000. | Q46581489 | ||
| Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia | Q47680919 | ||
| Diagnosis and treatment of KIT-mutant metastatic melanoma | Q47791808 | ||
| The Importance of Quality of Life Assessment | Q47900776 | ||
| Correlation between prognostic factors and increasing age in melanoma | Q48017574 | ||
| Malignant melanoma: the patient with an unknown site of primary origin | Q48447890 | ||
| BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma | Q48499411 | ||
| Distinctive features of melanoma and its management in elderly patients: a population-based study in France | Q50158049 | ||
| A long-term analysis of 620 patients with malignant melanoma at a major referral center. | Q50861630 | ||
| Decreased Survival Rates of Older-Aged Patients with Melanoma: Biological Differences or Undertreatment? | Q53558238 | ||
| Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. | Q53640355 | ||
| Cutaneous melanoma | Q56897036 | ||
| Melanoma | Q57571848 | ||
| Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors | Q58024613 | ||
| Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma | Q58024726 | ||
| Malignant melanoma in the elderly | Q69728112 | ||
| Head and neck melanoma in 534 clinical Stage I patients. A prognostic factors analysis and results of surgical treatment | Q70700834 | ||
| Unknown primary melanoma | Q71076952 | ||
| Clinical aspects of unknown primary melanoma | Q71131406 | ||
| Ras mutations in human melanoma: a marker of malignant progression | Q72273795 | ||
| Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma | Q73181804 | ||
| Complete regression of primary malignant melanoma | Q80935957 | ||
| Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006 | Q82139808 | ||
| BRAF and c-kit gene copy number in mutation-positive malignant melanoma | Q83221086 | ||
| Under-representation of older adults in cancer registration trials: known problem, little progress | Q84044139 | ||
| Morphological and molecular characteristics of nested melanoma of the elderly (evolved lentiginous melanoma) | Q84795413 | ||
| Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from Sweden | Q87574727 | ||
| Immunostimulatory monoclonal antibodies for cancer therapy | Q36717901 | ||
| International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer | Q36925135 | ||
| Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine | Q36980823 | ||
| RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors | Q37048053 | ||
| Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition | Q37237619 | ||
| Age-related lymphatic dysfunction in melanoma patients | Q37365007 | ||
| The role of immunity in elderly cancer | Q37541149 | ||
| Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma | Q37542216 | ||
| Spontaneous regression of metastases from melanoma: review of the literature | Q37562840 | ||
| Melanoma in the elderly patient: relevance of the aging immune system | Q37625415 | ||
| The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma | Q37626102 | ||
| Epidemiology and treatment of melanoma in elderly patients | Q37689491 | ||
| KIT as a therapeutic target in metastatic melanoma | Q37701887 | ||
| Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme | Q37718203 | ||
| Cancers with increasing incidence trends in the United States: 1999 through 2008. | Q37979107 | ||
| From genes to drugs: targeted strategies for melanoma | Q37999967 | ||
| Management of immune-related adverse events and kinetics of response with ipilimumab | Q38012057 | ||
| Metastatic melanoma in the older patient: special considerations | Q38100892 | ||
| Spontaneous regression of metastatic melanoma - clinical evidence of the abscopal effect | Q38153988 | ||
| Melanoma in 2013: Melanoma--the run of success continues | Q38178073 | ||
| Targeted therapies for cutaneous melanoma | Q38216373 | ||
| The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. | Q38270141 | ||
| Targeting RAS-ERK signalling in cancer: promises and challenges | Q38272894 | ||
| Sentinel Lymph Node Biopsy Use Among Melanoma Patients 75 Years of Age and Older | Q38401610 | ||
| Nivolumab in previously untreated melanoma without BRAF mutation | Q29620688 | ||
| Clinicopathologic characteristics and management trends of cutaneous invasive and in situ melanoma in older patients: a retrospective analysis of the National Cancer Data Base | Q30882472 | ||
| Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma | Q30890582 | ||
| The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society | Q31995716 | ||
| Improving melanoma classification by integrating genetic and morphologic features | Q33340639 | ||
| Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group | Q33372613 | ||
| Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma | Q33384029 | ||
| The pathogenesis of melanoma induced by ultraviolet radiation | Q33603082 | ||
| Increasing burden of melanoma in the United States | Q33836015 | ||
| Age as a prognostic factor in patients with localized melanoma and regional metastases | Q34000273 | ||
| Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients. | Q34010098 | ||
| Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. | Q34049618 | ||
| Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system | Q34086787 | ||
| Age-related changes in lymphocyte development and function | Q34293466 | ||
| Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma | Q34500495 | ||
| High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update | Q34507305 | ||
| Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model | Q34545994 | ||
| Somatic activation of KIT in distinct subtypes of melanoma | Q34569987 | ||
| The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma | Q34573029 | ||
| Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma | Q34625311 | ||
| Dabrafenib and its potential for the treatment of metastatic melanoma | Q34646614 | ||
| Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma | Q34664981 | ||
| Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities | Q34986093 | ||
| Genetic and morphologic features for melanoma classification | Q35024226 | ||
| BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site | Q35024230 | ||
| Malignant melanoma in the elderly: different regional disease and poorer prognosis. | Q35542768 | ||
| Melanoma in the Elderly Patient | Q35558765 | ||
| Systematic review of medical treatment in melanoma: current status and future prospects. | Q35584299 | ||
| Analysis of recurrence patterns in acral versus nonacral melanoma: should histologic subtype influence treatment guidelines? | Q35747918 | ||
| Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma | Q35801085 | ||
| Targeting the mitogen-activated protein kinase cascade to treat cancer | Q35968411 | ||
| Completely regressed primary cutaneous malignant melanoma with nodal and/or visceral metastases: a report of 5 cases and assessment of the literature and diagnostic criteria | Q36167562 | ||
| Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance | Q36489360 | ||
| Causes, consequences, and reversal of immune system aging | Q36638131 | ||
| P433 | issue | 10 | |
| P921 | main subject | metastatic melanoma | Q18975855 |
| P304 | page(s) | 821-834 | |
| P577 | publication date | 2015-10-06 | |
| P1433 | published in | Drugs & Aging | Q5308946 |
| P1476 | title | Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients | |
| P478 | volume | 32 |
| Q37685111 | Baicalein Inhibits the Migration and Invasion of B16F10 Mouse Melanoma Cells through Inactivation of the PI3K/Akt Signaling Pathway |
| Q37295749 | High fat diet increases melanoma cell growth in the bone marrow by inducing osteopontin and interleukin 6 |
| Q38801272 | Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma |
| Q96134051 | Nivolumab in metastatic melanoma: good efficacy and tolerability in elderly patients |
Search more.